中肽生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
PARP-008B
PAR-3 (1-6) amide (human)
Thr-Phe-Arg-Gly-Ala-Pro-NH2 Trifluoroacetate salt
Thr-Phe-Arg-Gly-Ala-Pro-NH2 Trifluoroacetate salt
Size：25mg
P1(RMB)：2090
MW：646.75
One letter sequence：TFRGAP-NH2
Molecular Formula：C29H46N10O7
Description：This peptide is a human PAR-3-derived tethered ligand, which does not activate PAR-3 but rather activates PAR-1 and PAR-2, either in Jurkat or in other PAR-expressing cells. PAR3 Tethered Ligand (Human) / Activates PAR1 and PAR2 This peptide is the 1-6 fragment of the protease-activated receptor 3 (PAR-3), which induces ERK activation in human carcinoma cells endogeneously expressing PAR1 and PAR3. This effect is completely abolished by single alanine substitution at positions 3, 4 and 6 in the peptide. PAR-3 allosterically regulates PAR1 signaling by receptor dimerization governing increased endothelial permeability. Targeting of PAR3 may mitigate the effects of PAR1 in activating endothelial responses such as vascular inflammation. However this peptide does not affect VEGF release or expression.
Literature Reference：K.K.Hansen et al., Immunology, 112, 183 (2004) Kaufmann, R. et al. Regul. Pept. 125, 61( 2005) McLaughlin, J. et al. PNAS 104, 5662 (2007) Arisato, T. et al. Cell. Mol. Life Sci. 60, 1420 (2003)
Cas：
P1(RMB)：2090
MW：646.75
One letter sequence：TFRGAP-NH2
Molecular Formula：C29H46N10O7
Description：This peptide is a human PAR-3-derived tethered ligand, which does not activate PAR-3 but rather activates PAR-1 and PAR-2, either in Jurkat or in other PAR-expressing cells. PAR3 Tethered Ligand (Human) / Activates PAR1 and PAR2 This peptide is the 1-6 fragment of the protease-activated receptor 3 (PAR-3), which induces ERK activation in human carcinoma cells endogeneously expressing PAR1 and PAR3. This effect is completely abolished by single alanine substitution at positions 3, 4 and 6 in the peptide. PAR-3 allosterically regulates PAR1 signaling by receptor dimerization governing increased endothelial permeability. Targeting of PAR3 may mitigate the effects of PAR1 in activating endothelial responses such as vascular inflammation. However this peptide does not affect VEGF release or expression.
Literature Reference：K.K.Hansen et al., Immunology, 112, 183 (2004) Kaufmann, R. et al. Regul. Pept. 125, 61( 2005) McLaughlin, J. et al. PNAS 104, 5662 (2007) Arisato, T. et al. Cell. Mol. Life Sci. 60, 1420 (2003)
Cas：
